top of page

R&A PSYINS and Psychedelic Invest Host “Trials and Triumphs of Operating a Ketamine Clinic” Webinar

R&A PSYINS, an independent insurance broker focused exclusively on the psychedelic medicinal industry, in partnership with Nucleus Holding, Inc. “(Nucleus”), a venture studio which owns and operates a portfolio of companies that connects stakeholders within the psychedelics industry, released a webinar on the Nucleus Psychedelic Invest network entitled “Trials and Triumphs of Operating a Ketamine Clinic.”


Synopsis:


Countless studies have been conducted on Ketamine-Assisted Psychotherapy (KAP) with evidence supporting it as a promising and effective treatment for patients suffering from chronic pain and medication-resistant mental health disorders, such as anxiety, depression, and PTSD. This has led to unprecedented growth in the number of private clinics that now offer KAP. Today, an estimated 1,200 to 1,500 ketamine clinics operate in the U.S., compared to 60 clinics in 2015. Despite KAP entering the mainstream, as with most new interventions, it’s considered high risk for a myriad of reasons.


This webinar provides an opportunity to hear from experienced operators of ketamine clinics throughout the country share their journey on starting and administering ketamine-assisted therapy.


Moderators:

Panelists:

To access the webinar, click here or on any of the links below:



R&A PSYINS is at the forefront of this new psychedelic movement providing licensed practitioners, ketamine clinics, psychedelic retreats, drug manufacturers and testing facilities with custom Business Liability Insurances. Click here to schedule a consultation with Eric Rahn.

Comments


bottom of page